Efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension.
Zhi-Cheng Jing,Geoff Strange,Xian-Yang Zhu,Da-Xin Zhou,Jie-Yan Shen,Hong Gu,Zhen-Kun Yang,Xin Pan,Mei-Xiang Xiang,Hua Yao,Dong-Bao Zhao,Brad S Dalton,Zhuo-Li Zhang,Yong Wang,Xian-Sheng Cheng,Yue-Jin Yang
DOI: https://doi.org/10.1016/j.healun.2009.09.020
IF: 13.569
2010-01-01
The Journal of Heart and Lung Transplantation
Abstract:BACKGROUND: Bosentan has an established role in the management of pulmonary arterial hypertension (PAH). This clinical trial assessed the benefits of bosentan in the Chinese population. METHODS: We investigated the efficacy and safety of bosentan in 92 Chinese citizens (mean +/- standard deviation age, 29.0 +/- 3.8 years) with PAH for a minimum of 12 weeks. All received bosentan (62.5 mg twice daily) for 4 weeks; then, patients who weighed <40 kg received 62.5 mg bosentan twice daily and patients who weighed >40 kg received 125 mg twice daily. All patients were eligible to continue bosentan beyond 12 weeks. The primary end point was a chance in exercise capacity from baseline to 12 and 24 weeks. Secondary end points included a change in World Health Organization (WHO) functional class and changes in cardiopulmonary hemodynamics. RESULTS: At baseline, 66 patients (72%) were in WHO functional class III; presentation was 37 (40%) with idiopathic PAH (iPAH), 34 (37%) with PAH related to congenital heart disease (CHD), and 21 (23%) with PAH related to connective tissue disease (CTD). Exercise capacity increased to 67.8 m after 12 weeks and 92.6 m after 24 weeks (p < 0.001). After 24 weeks, WHO functional class decreased (-0.8 +/- 0.6; p < 0.001), mean pulmonary artery pressure and pulmonary vascular resistance decreased (p < 0.01), ana cardiac output increased (p < 0.001). Twelve patients (13%) experienced at least 1 adverse event. CONCLUSIONS: Bosentan improved exercise capacity, functional class, and cardiopulmonary hemodynamics in this patient cohort and was well tolerated. J Heart Lung Transplant 2010;29:150-6 (C) 2010 International Society for Heart and Lung Transplantation. All rights reserved.